Evidence map›Paper›PMID 27843312›Full record

ArticleInternational journal of nanomedicine

Formulation, characterization and tissue distribution of a novel pH-sensitive long-circulating liposome-based theranostic suitable for molecular imaging and drug delivery.

Yin Duan, Lihui Wei, Julia Petryk, Terrence D Ruddy

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 32 citations in OpenAlex.

  1. Radiolabeled Liposomes for Nuclear Imaging Probes.Molecules (Basel, Switzerland) · 2023
    Review
  2. Article
  3. Article
  4. Article
  5. Journal of drug delivery science and technology · 2020
    Article
  6. Development of an inflammation imaging tracer,Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019
    Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Yin DuanNordion Inc.; Cardiac Positron Emission Tomography (PET) Radiochemistry Research Core Laboratory, Canadian Molecular Imaging Center of Excellence, University of Ottawa Heart Institute.
Lihui WeiNordion Inc.; Cardiac Positron Emission Tomography (PET) Radiochemistry Research Core Laboratory, Canadian Molecular Imaging Center of Excellence, University of Ottawa Heart Institute; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada.
Julia PetrykCardiac Positron Emission Tomography (PET) Radiochemistry Research Core Laboratory, Canadian Molecular Imaging Center of Excellence, University of Ottawa Heart Institute; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada.
Terrence D RuddyCardiac Positron Emission Tomography (PET) Radiochemistry Research Core Laboratory, Canadian Molecular Imaging Center of Excellence, University of Ottawa Heart Institute; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada.
University of Ottawa · CANordion (Canada) · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWhen designing liposome formulas for treatment and diagnostic purposes, two of the most common challenges are 1) the lack of a specific release mechanism for the encapsulated contents and 2) a short circulation time due to poor resistance to biological fluids. This study aimed to create a liposome formula with prolonged in vivo longevity and pH-sensitivity for cytoplasmic drug delivery. MATERIALS AND

methodsLiposomal particles were generated using hydrogenated soy (HS) phosphatidylcholine, cholesteryl hemisuccinate (CHEM), polyethylene glycol (PEG) and diethylenetriaminepentaacetic acid-modified phosphatidylethanolamine with film hydration and extrusion methods. The physicochemical properties of the different formulas were characterized. pH-sensitivity was evaluated through monitoring release of encapsulated calcein. Stability of the radiolabeled liposomes was assessed in vitro through incubation with human serum. The best formula was selected and injected into healthy rats to assess tissue uptake and pharmacokinetics.

resultsLiposomal particles were between 88 and 102 nm in diameter and negatively charged on the surface. Radiolabeling of all formulas with indium-111 was successful with good efficiency. 1%PEG-HS-CHEM not only responded to acidification very quickly but also underwent heavy degradation with serum. The 4%PEG-HS-CHEM, which exhibited both comparatively good pH-sensitivity (up to 20% release) and satisfactory stability (stability >70% after 24 h), was considered the best candidate for in vivo evaluation. Tissue distribution of 4%PEG-HS-CHEM was comparable to that of 4%PEG-HS-Chol, a long-circulating but pH-insensitive control, showing major accumulation in liver, spleen, intestine and kidneys. Analysis of blood clearance showed favorable half-life values: 0.6 and 14 h in fast and slow clearance phases, respectively.

conclusion4%PEG-HS-CHEM showed promising results in pH-sensitivity, serum stability, tissue uptake and kinetics and is a novel liposome formulation for multifunctional theranostic applications.

Indexed as

AnimalsCholesterol EstersDrug Delivery SystemsFluoresceinsHalf-LifeHydrogen-Ion ConcentrationIndium RadioisotopesLiposomesMaleMolecular ImagingPentetic AcidPhosphatidylethanolaminesPolyethylene GlycolsRats, Sprague-DawleyTheranostic NanomedicineTissue DistributionCholesterol Esterscholesteryl succinatediethylenetriaminetetraacetic acidFluoresceinsfluorexonIndium RadioisotopesLiposomesPentetic AcidphosphatidylethanolaminePhosphatidylethanolaminesPolyethylene Glycolscholesteryl hemisuccinatehydrogenated soy phosphatidylcholinelong in vivo half-lifePEGylated liposomepH-triggered release

Identifiers

PMID27843312
PMCPMC5098928
OpenAlexW2547072980

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.